


















patients	were	males	 (65.7%)	 and	mean	 logistic	 Euroscore	was	 8.35	 +	 15.8%.	 Valve	 lesions	were	mainly	
stenosis	(24	patients;	68.6%),	regurgitation	(7	patients;	20%)	and	mixed	aortic	lesions	(4	patients;	11.4%).	
Implanted	prostheses	were	19	bioprosthesis	 (54.2%)	and	16	mechanical	valves	 (45.8%).	We	had	one	30-
days	mortality	 (2.8%),	 13	 postoperative	 new	onset	 atrial	 fibrillation	 (37%),	 permanent	 pacemaker	 2.8%,	
cerebrovascular	 stroke	 2.8%,	 re	 sternotomy	 for	 bleeding	 2.8%	 and	 two	 patients	 needed	 hemodialysis	
(5.7%).	Patients	were	 followed	up	 for	0.9	+	1.2	years.	When	 last	 seen,	27	patients	were	 in	NYHA	class	 I	
(77.1%),	 six	patients	were	 in	class	 II	 (17.1%)	and	 two	patients	with	moderate	 to	severe	PVL	 remained	 in	
NYHA	class	 IV	 (5.7%).	Peak	aortic	valve	gradients	 ranged	 from	14	 to	68	mmHg,	with	a	mean	gradient	of	
27.8	+	13.3	mm	Hg.	Three	patients	with	trivial	PVL	(8.5%)	developed	prosthetic	valve	endocarditis,	with	2	











Paravalvular	 leak	 (PVL)	 is	 a	 well-
recognized	 complication	 of	 conventional	 aortic	
valve	 replacement	 surgery	 (AVR)	 [1-3].	 The	
incidence	 of	 PVL,	 including	 small	 non-significant	
jets,	is	estimated	to	be	as	high	as	20%	[4-5].	Most	
PVLs	 are	 hemodynamically	 non-significant;	
however	 moderate	 or	 severe	 PVL	 can	 lead	 to	
heart	 failure	 and	 increased	 risk	 of	 infective	
endocarditis.	 Smaller	 PVLs	 may	 cause	
intravascular	haemolysis	and	anaemia.	[6-8].	
Increasingly,	AVR	is	being	performed	by	a	
variety	 of	 new	 techniques.	 These	 include	
insertion	 of	 conventional	 prosthesis	 via	 minimal	
access	 approaches	 for	 example;	 right	 lateral	





sutureless	 prosthesis	 via	 conventional	 median	
sternotomy	 and	 minimal	 access	 routes	 and	
percutaneous	 valve	 insertion	 via	 transfemoral,	
transapical	or	trans-aortic	routes	(TAVI)	[9-11].	In	
this	study	we	set	out	evaluate	the	incident	of	PVL	
in	 our	 practice	 and	 to	 determine	 the	 prognosis	




This	 was	 a	 retrospective	 study	 of	
prospectively	 collected	 data	 from	 our	
institutional	 database.	 The	 data	 is	 prospectively	
collected	 for	 the	 United	 Kingdom	 adult	 cardiac	
surgical	 database.	 From	 January	 2008	 to	
December	 2014,	 460	 consecutive	 patients	
benefited	 from	 aortic	 valve	 replacement.	 They	
were	 262	 males	 (57%)	 and	 198	 females	 (43%)	
with	a	mean	age	62.9	+	15.6	 years	 (range	17-84	
years).	 The	 primary	 aetiology	 for	 valvular	
dysfunction	 was	 degenerative	 in	 337	 (73.3%),	
bicuspid	 aortic	 valve	 in	 104	 (22.6%),	 infective	
endocarditis	 in	 16	 (3.5%),	 and	 rheumatic	 valve	
disease	 in	 4	 (0.9%).	 The	 underlying	 valvular	






Valve	 insertion	 techniques	 were	 similar	
among	 the	 seven	 operating	 surgeons	 in	 our	
institution	 during	 the	 study	 period.	 In	 general,	
stented	 prosthesis	 were	 inserted	 using	
interrupted	mattress	sutures	to	place	the	valve	in	
a	 supra	 aortic	 position.	 Braided	non-	 absorbable	
suture	 were	 used.	 Felt	 pledgets	 were	 not	
routinely	 used	 but	 were	 employed	 where	 the	
operative	 surgeon	 felt	 they	 were	 required	 for	
patients	 with	 poor	 tissue	 quality.	 As	 shown	 in	
Table	1,	the	aortic	valve	was	replaced	with	either	
mechanical	 (133	 patients;	 29.0%)	 or	 biological	
valve	 prosthesis	 (327	 patients;	 71.0%).	 Patient’s	
age,	 preference	 and	 Surgeon	 choice	 were	 the	




It	 was	 our	 routine	 practice	 to	 perform	 a	
transthoracic	 echocardiogram	 prior	 to	 discharge	
for	 all	 AVR	 cases.	 PVL	 was	 defined	 as	 a	
regurgitant	 jet	between	the	annulus	of	the	valve	
and	 the	 valve	 sewing	 ring.	 Patients	 who	 were	
identified	 to	 have	 a	 PVL	 underwent	
transoesophageal	 echocardiograms	 to	 further	
assessment	of	 the	PVL.	The	 latter	was	graded	as	
trivial,	mild,	moderate	or	 severe	based	on	visual	
estimation	 and	 the	 diastolic	 slope	 of	 aortic	
regurgitation	 detected	 by	 continuous	 flow	
Doppler.		
	






















PVL	 was	 trivial	 in	 18	 (51.4%),	 mild	 in	 14	 (40%),	
moderate	 in	 2	 (5.7%)	 and	 severe	 in	 1	 patient	
(2.9%).	 The	 PVL	 group	 did	 not	 differ	 from	 the	
entire	cohort	of	460	patients	 in	demographics	or	
perioperative	 risk	 profile;	 65.7%	were	male,	 and	
mean	 age	 was	 62.9	 +	 15.6	 years.	 Mean	 logistic	





stenosis	 (68.6%),	 regurgitation	 (20%),	 and	mixed	
(11.4%).	 Aortic	 prostheses	were	 bioprosthetic	 in	
54%	and	mechanical	 in	46%.	Other	demographic	
and	 operative	 variables	 are	 shown	 in	 Table	 2.	
There	 was	 no	 difference	 in	 incidence	 of	 PVL	 in	
AVR	 cases	 done	 by	 surgical	 trainees	 or	
consultants	(7/113)	(6.2%)	versus	28/347	(8%).		
Table	 2:	 Demographics	 and	 operative	



























































In	 concordance,	 postoperative	 outcomes	
in	 the	 PVL	 patients	 were	 not	 significantly	
different	to	the	entire	cohort.	As	shown	in	Table	
3,	 30-days	 mortality	 was	 2.8%.	 Morbidity	 was	
new	 onset	 atrial	 fibrillation	 in	 37%,	 permanent	
pacemaker	 2.8%,	 stroke	 2.8%,	 haemodialysis	
5.7%	 and	 re	 sternotomy	 for	 bleeding	 2.8%.	
Postoperative	peak	aortic	valve	gradients	ranged	
from	14	to	68	mmHg.	At	a	mean	follow-up	of	0.9	
+	 1.2	 years	 for	 all	 patients,	 NYHA	 class	 was	 I,	 II	
and	 IV	 in	 77.1%,	 17.1%	 and	 5.7%	 respectively.	
Two	 patients	 with	 moderate	 and	 severe	 PVL	
remained	 in	NYHA	 IV.	 Three	patients	with	 trivial	
PVL	 developed	 prosthetic	 valve	 endocarditis	













































PVL	 is	 the	 most	 common	 form	 of	 non-
structural	 prosthetic	 valve	 dysfunction	 [12,	 13].	
There	 are	 several	 hypotheses	 for	 the	
pathogenesis	 of	 early	 onset	 PLV	 in	 absence	 of	
infection.	 	 Technical	 factors	 including	 knot	
disruption,	 inadequate	 suture	 placement	 or	
extensive	 annular	 de-calcification	 impeding	
adequate	 apposition	 of	 the	 valve	 against	 the	
uneven	 annulus.	 Annulus	 tissue	 retraction	 from	
the	 sewing	 ring	 between	 sutures	 during	 healing	
has	 been	proposed	 as	 a	 cause	of	 late	 onset	 PVL	
[14].	 Interestingly,	 the	 St.	 Jude	Medical	 bileaflet	




normal	 fibroblast	 response	 and	 incorporation	 of	
the	 sewing	 cuff	 fabric	 into	 the	 annular	 tissue	 in	
some	patients	[15,	16].	
Our	 series	 confirms	 that	 the	 incidence	 of	
moderate	or	greater	PVL	after	 conventional	AVR	
is	 low,	 0.65%	 in	our	 series.	 Trivial	 or	mild	PVL	 is	
more	 common,	 approximately	 6.9%.	 However,	
these	 patients	 with	 trivial	 or	 mild	 PVL	 have	 a	
mostly	 benign	 post-operative	 course	 during	 the	
follow	period.		




and	 sutureless	 aortic	 valve	 replacements.	 TAVI	
has	 been	 associated	 with	 significantly	 higher	
incidence	 of	 PVL	 compared	 with	 conventional	
surgery.	 In	 the	 5	 years	 data	 for	 the	 PARTNER	 A	
trial,	 the	 incidence	 of	 moderate	 or	 greater	 PVL	
was	around	40%.	These	patients	had	a	higher	risk	
of	 death	 	 compared	 with	 patients	 with	 no	 PVL.	
Interestingly	 even	mild	 PVL	 was	 associated	with	
an	increased	risk	of	mortality	[17,	18].	
Sutureless	 aortic	 valve	 prosthesis	
implanted	 via	 conventional	 median	 sternotomy	
or	 minimally	 invasive	 approaches	 may	 also	
potentially	 decrease	 the	 complications	 of	 AVR	
particularly	in	high-risk	patients	[18].	Because	the	



































































decalcified	 it	 is	 likely	 that	 PVL	 rates	 after	
sutureless	 valve	 insertion	 will	 be	 less	 that	 after	
TAVI.	 Indeed,	 although	 experience	 with	 these	
valves	have	been	currently	limited	to	few	centers,	
reported	PVL	rates	after	sutureless	AVR	is	around	
5%	 with	 rates	 of	 moderate	 or	 greater	 PVL	
reported	 as	 2-3%	 [19,	 20].	 There	 has	 been	 no	
data	 as	 yet	 to	 determine	 the	 prognosis	 of	 the	
patients	with	PVL	after	sutureless	AVR.	
Conventional	 AVR	 carries	 low	 mortality,	
low	morbidity,	 low	 PVL	 rates,	 and	 has	 excellent	
long	 term	 results.	 However,	 this	 treatment	 has	
traditionally	only	been	available	 to	 relatively	 ‘fit’	
patients.	 TAVI	 and	 sutureless	 AVR	 have	
significantly	 increased	 the	 spectrum	 of	 patients	
who	 can	 have	 intervention	 for	 aortic	 valve	
disease.	These	 techniques	are	 in	 the	early	phase	
of	 clinical	 use	 and	 it	 is	 likely	 that	 there	 will	 be	
significant	 improvements	 in	 the	 technology	 and	





The	main	 limitation	of	our	study	 is	that	 it	
is	a	 retrospective	review	of	echo	data.	However,	
each	TTE	was	re-examined	to	ensure	accuracy	of	
the	 data.	 Although	 valve	 insertion	 techniques	
were	relatively	standard	during	the	study	period,	
variations	 in	 these	 techniques	 dictated	 by	
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